Phathom Pharmaceuticals, Inc. (PHAT)

Market Cap	1.00B +124.4%
Revenue (ttm)	175.11M +216.9%
Net Income	-221.25M
EPS	-3.03
Shares Out	79.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,441,312
Open	12.83
Previous Close	12.64
Day's Range	12.51 - 13.19
52-Week Range	2.21 - 18.31
Beta	0.61
Analysts	Strong Buy
Price Target	19.83 (+57.01%)
Earnings Date	Apr 30, 2026

About PHAT

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-eros...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 371
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAT
• Website: https://www.phathompharma.com

Financial Performance

In 2025, Phathom Pharmaceuticals's revenue was $175.11 million, an increase of 216.93% compared to the previous year's $55.25 million. Losses were -$221.25 million, -33.82% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price target is $19.83, which is an increase of 57.01% from the latest price.

Price Target

$19.83

(57.01% upside)

Analyst Consensus: Strong Buy